20. U.S. Food and Drug Administration. FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use. https://www.fda.gov/news-events/ press-announcements/fda-requires-strong- warnings-opioid-analgesics-prescription- opioid-cough-products-and-benzodiazepine. Published August 31, 2016. Accessed August 17, 2021. epidemiology: Benzodiazepine prescribing and the drug overdose epidemic in the United States. Pharmacoepidemiol Drug Saf. 2018. 22. US Department of Justice, Drug Enforcement Administration, Office of Diversion Control. Practitioner’s Manual. 2006 Edition. 23. Code of Federal Regulations, Title 21 CFR 21. Zoorob MJ. Polydrug §1306 Prescriptions §1306.04. https:// www.deadiversion.usdoj.gov/21cfr/ cfr/1306/1306_04.htm. Accessed June 11, 2021. 24. Dispensing Controlled Substances for the Treatment of Pain, DEA Policy Statement, 71 Fed. Reg. 52716, 52717. Sept. 6, 2006. 25. Centers for Medicare and Medicaid Services. Partners in Integrity: What is a Prescriber’s Role in Preventing the Diversion of Prescription Drugs? https://www.pharmacy.umn.edu/sites/ pharmacy.umn.edu/files/prescriber_role_in_ preventing_diversion.pdf Accessed June 30, 2021. Health. Tennessee’s Annual Overdose Report 2021: Report on Epidemiologic Data and Projects to Address the Overdose Epidemic. https://www.tn.gov/content/dam/tn/health/ documents/pdo/2021%20TN%20Annual%20 Overdose%20Report.pdf. Accessed January 5, 2022. 27. Centers for Disease Control and Prevention. 26. Tennessee Department of U.S. State Opioid Dispensing Rates, 2020. https://www.cdc.gov/drugoverdose/rxrate- maps/state2020.html. Accessed January 5, 2022. 28. Tennessee Department of Health. Neonatal Abstinence Syndrome Surveillance Annual Report 2020. https://www.tn.gov/content/ dam/tn/health/documents/nas/NAS-Annual- Report-2020.pdf. Accessed January 5, 2022. 29. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923. 30. Murray BP, Carpenter JE, Dunkley CA, et al. Seizures in tramadol overdoses reported in the ToxIC registry: predisposing factors and the role of naloxone. Clin Toxicol (Phila). 2019;57(8):692-696. 31. Hassanian-Moghaddam H, Farajidana H, Sarjami S, Owliaey H. Tramadol-induced apnea. Am J Emerg Med. 2013;31(1):26-31. 32. Shadnia S, Soltaninejad K, Heydari K, Sasanian G, Abdollahi M. Tramadol intoxication: a review of 114 cases. Hum Exp Toxicol. 2008;27(3):201-205.
33. Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain. 2017. 34. Argoff CE, Silvershein DI. A Comparison of Long- and Short-Acting Opioids for the Treatment of Chronic Noncancer Pain: Tailoring Therapy to Meet Patient Needs. Mayo Clin Proc. 2009;84(7):602-612. 35. U.S. Food and Drug Administration. Extended-release (ER) and long-acting (LA) opioid analgesics risk evaluation and mitigation strategy (REMS). https://www. fda.gov/downloads/Drugs/DrugSafety/.../ UCM311290.pdf. Published June 2015. Accessed 11-28-18. 36. U.S. Food and Drug Administration. FDA Briefing Document: Joint Meeting of the Drug Safety and Risk Management (DSaRM) Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC): Extended-release and Long-acting (ER/LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS). https:// www.fda.gov/AdvisoryCommittees/Calendar/ ucm490628.htm. Published May 3-4, 2016. Accessed 3-7-18. 37. Centers for Disease Control and Prevention. Preventing an opioid overdose. https://www. cdc.gov/drugoverdose/.../Preventing-an- Opioid-Overdose-Tip-Card-a.pdf. Accessed 3-20-18. 38. Rolfs RT, Johnson E, Williams NJ, Sundwall DN. Utah clinical guidelines on prescribing opioids for treatment of pain. J Pain Palliat Care Pharmacother. 2010;24(3):219-235. 39. Hatten BW, Cantrill SV, Dubin JS, et al. Clinical Policy: Critical Issues Related to Opioids in Adult Patients Presenting to the Emergency Department. Ann Emerg Med. 2020;76(3):e13-e39. 40. Washington State Agency Medical Directors’ Group. Interagency Guideline on Prescribing Opioids for Pain, 3rd ed. 2015. 41. Tennessee Department of Health. Clinical Practice Guidelines for Outpatient Management of Chronic Non-malignant Pain 3-TR Ed. 2020. 42. Nicolaidis C. Police officer, deal-maker, or health care provider? Moving to a patient-centered framework for chronic opioid management. Pain medicine. 2011;12(6):890-897. 43. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. The Cochrane database of systematic reviews. (1):CD006605. 44. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130. 45. U.S. Food and Drug Administration. FDA announces enhanced warnings for immediate- release opioid pain medications related to risks of misuse, abuse, addiction, overdose and death. https://www.fda.gov/news-events/ press-announcements/fda-announces- enhanced-warnings-immediate-release- opioid-pain-medications-related-risks-misuse- abuse Published March 22, 2016. Accessed April 27, 2021.
46. U.S. Food and Drug Administration. New safety measures announced for extended-release and long-acting opioids. http://www.fda.gov/ Drugs/DrugSafety/InformationbyDrugClass/ ucm363722.htm. 47. Conway BR, Fogarty DG, Nelson WE, Doherty CC. Opiate toxicity in patients with renal failure. BMJ. 2006;332(7537):345-346. 48. Federation of State Medical Boards (FSMB). Guidelines for the chronic use of opioid analgesics. https://www.fsmb.org/opioids/. Published April 2017. Accessed January 26, 2021. 49. Agency for Healthcare Quality and Research (AHRQ). Choosing nonopioid analgesics for osteoarthritis: clinician summary guide. J Pain Palliat Care Pharmacother. 2009;23(4):433- 457. 50. Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med. 2016;17(1):85- 98. 51. Jones CM, McAninch JK. Emergency Department Visits and Overdose Deaths From Combined Use of Opioids and Benzodiazepines. Am J Prev Med. 2015;49(4):493-501. 52. Institute of Medicine Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. In. Washington (DC): National Academies Press (US); 2011. 53. Scholz J, Finnerup NB, Attal N, et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019;160(1):53-59. 54. Substance Abuse and Mental Health Services Administration: SAMHSA Opioid Overdose Prevention Toolkit. HHS Publication No. (SMA) 13–4742. Rockville M, 2013, Substance Abuse and Mental Health Services Administration. In. 55. Webster LR, Cochella S, Dasgupta N, et al. An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Med. 2011;12 Suppl 2:S26-35. 56. Porucznik CA, Johnson EM, Sauer B, Crook J, Rolfs RT. Studying adverse events related to prescription opioids: the Utah experience. Pain Med. 2011;12 Suppl 2:S16-25. 57. Zedler BK, Saunders WB, Joyce AR, Vick CC, Murrelle EL. Validation of a screening risk index for serious prescription opioid-induced respiratory depression or overdose in a US commercial health plan claims database. Pain Med. 2017. 58. Ogbru A. Benzodiazepines. RxList. https:// www.rxlist.com/benzodiazepines/drug-class. htm Accessed July 22, 2021. 59. Covington EC, Argoff CE, Ballantyne JC, et al. Ensuring Patient Protections When Tapering Opioids: Consensus Panel Recommendations. Mayo Clin Proc. 2020;95(10):2155-2171.
17
Powered by FlippingBook